Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer

Publication Date: January 5, 2023
Last Updated: May 30, 2023

Treatment

First-line Therapy

Recommendation 1.1

For HER2-negative patients with gastric adenocarcinoma and PD-L1 combined positive score (CPS) ≥5, first-line therapy with nivolumab in combination with fluoropyrimidine- and platinum-based chemotherapy is recommended. (EB, B, M, S)
Qualifying statements:
  • For HER2-negative patients with gastric adenocarcinoma and PD-L1 CPS 1–5, first-line therapy with nivolumab in combination with fluoropyrimidine- and platinum-based chemotherapy may be considered on a case-by-case basis.
  • For patients with gastric adenocarcinoma and PD-L1 CPS 0, first-line therapy with fluoropyrimidine- and platinum-based chemotherapy, without the addition of nivolumab, is recommended.
1048203

Video

Overview

Title

Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer

Authoring Organization